Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation

PHASE1,PHASE2

Phase

TERMINATED

Status

Enrollment

OTHER

Sponsor class

Stopped Enrolling 8 more patients would be statistically unlikely that the primary endpoint would be reached (reduce day 180 grade II-IV GVHD rates to 20% or less)

Conditions

Leukemia, Myeloid, Acute
Myelodysplastic Syndromes
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Interventions

DRUG: Azacitidine

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]
[object Object]